A high tumor mutation burden (TMB) consistently correlated with a higher incidence of durable clinical response (DCR) and improved survival after treatment with anti-CTLA-4 or anti-PD-L1 ICIs for cancers which are known to harbor a higher level of somatic mutations (50–54). Here, CTLA4 is linked to neoplasm.